BioCardia, Inc. (BCDA): Price and Financial Metrics
BCDA Price/Volume Stats
| Current price | $0.67 | 52-week high | $2.92 |
| Prev. close | $0.68 | 52-week low | $0.36 |
| Day low | $0.62 | Volume | 194,210 |
| Day high | $0.69 | Avg. volume | 747,302 |
| 50-day MA | $0.49 | Dividend yield | N/A |
| 200-day MA | $1.43 | Market Cap | 14.48M |
BCDA Stock Price Chart Interactive Chart >
BCDA Stock Summary
- BCDA has a higher market value than only 5.68% of US stocks; more precisely, its current market capitalization is $8,431,578.
- BIOCARDIA INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.56% of US listed stocks.
- Revenue growth over the past 12 months for BIOCARDIA INC comes in at -56.98%, a number that bests just 4.13% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to BIOCARDIA INC, a group of peers worth examining would be GSIT, CRIS, DTIL, MRKR, and SMR.
- BCDA's SEC filings can be seen here. And to visit BIOCARDIA INC's official web site, go to www.biocardia.com.
BCDA Valuation Summary
- In comparison to the median Healthcare stock, BCDA's price/sales ratio is 1088.24% higher, now standing at 20.2.
- Over the past 243 months, BCDA's price/earnings ratio has gone up 141.8.
Below are key valuation metrics over time for BCDA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BCDA | 2023-11-03 | 20.2 | 5.3 | -0.7 | -0.4 |
| BCDA | 2023-11-02 | 19.1 | 5.0 | -0.6 | -0.4 |
| BCDA | 2023-11-01 | 19.3 | 5.0 | -0.6 | -0.4 |
| BCDA | 2023-10-31 | 18.8 | 4.9 | -0.6 | -0.4 |
| BCDA | 2023-10-30 | 19.3 | 5.0 | -0.6 | -0.4 |
| BCDA | 2023-10-27 | 19.3 | 5.0 | -0.6 | -0.4 |
BCDA Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at 7.74%.
- The 2 year net income to common stockholders growth rate now stands at 17%.
- The 5 year net cashflow from operations growth rate now stands at -26.48%.
The table below shows BCDA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.325 | -10.539 | -12.34 |
| 2022-06-30 | 1.934 | -11.176 | -11.989 |
| 2022-03-31 | 1.029 | -11.396 | -12.979 |
| 2021-12-31 | 1.015 | -10.366 | -12.623 |
| 2021-09-30 | 0.982 | -10.808 | -12.151 |
| 2021-06-30 | 0.195 | -11.769 | -13.293 |
BCDA Price Target
For more insight on analysts targets of BCDA, see our BCDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $11.17 | Average Broker Recommendation | 1.62 (Moderate Buy) |
BioCardia, Inc. (BCDA) Company Bio
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Latest BCDA News From Around the Web
Below are the latest news stories about BIOCARDIA INC that investors may wish to consider to help them evaluate BCDA as an investment opportunity.
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesSUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share of common stock in a registered direct offering pr |
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure StudyThe FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure. |
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart FailureSUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure. BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart F |
BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call TranscriptBioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript November 8, 2023 BioCardia, Inc. reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Ladies and gentlemen, thank you for standing by and welcome to the BioCardia 2023 Third Quarter Conference Call. At this time, all participants are in a listen-only mode. […] |
Q3 2023 BioCardia Inc Earnings CallQ3 2023 BioCardia Inc Earnings Call |
BCDA Price Returns
| 1-mo | 79.96% |
| 3-mo | -13.98% |
| 6-mo | -64.55% |
| 1-year | -63.78% |
| 3-year | -71.49% |
| 5-year | -95.86% |
| YTD | -67.94% |
| 2022 | 7.73% |
| 2021 | -43.93% |
| 2020 | -5.98% |
| 2019 | -65.93% |
| 2018 | -48.94% |
Continue Researching BCDA
Here are a few links from around the web to help you further your research on BioCardia Inc's stock as an investment opportunity:BioCardia Inc (BCDA) Stock Price | Nasdaq
BioCardia Inc (BCDA) Stock Quote, History and News - Yahoo Finance
BioCardia Inc (BCDA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...